Ignite Creation Date:
2024-05-06 @ 7:44 PM
Last Modification Date:
2024-10-26 @ 3:13 PM
Study NCT ID:
NCT06125977
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-11-18
First Post:
2023-02-13
Brief Title:
Impact of Non-Exudative Type 1 MNV on AMD Progression
Sponsor:
University of Utah
Organization:
University of Utah
Study Overview
Official Title:
The Impact of Non-Exudative Type 1 Macular Neovascularization MNV on Age-related Macular Degeneration AMD Progression
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The overall goal of the proposed research project is to provide evidence that a specific subtype of neovascularization that may develop in eyes with age-related macular degeneration AMD prevents vision loss
This concept challenges the current view that the development of neovascularizations in AMD represents a harmful event in general Notably before the era of anti-vascular endothelial growths factor VEGF therapy destruction and surgical removal of neovascular membranes have been tested as treatment options for neovascular AMD
This research project aims to substantiate the hypothesis that type 1 macular neovascularization MNV is intrinsically protective in sense of a positive response to the degenerative processes in AMD This concept has actually been proposed by pathologists decades ago but has not been systematically investigated in vivo
With the immense advances in retinal imaging sub-clinical non-exudative type 1 MNVs that are located beneath the retinal pigment epithelium RPE can now be detected non-invasively and characterized in vivo There is currently a growing body of evidence that photoreceptor and RPE degeneration is indeed slowed down in eyes exhibiting type 1 MNV However the proof of a direct protective effect of non-exudative type 1 MNV on visual function in AMD is lacking
Here the aim is to demonstrate relative preservation of function along with preserved structure in the immediate vicinity of type 1 MNV while there is progressive loss of sensitivity and degeneration in the surrounding tissue
This concept challenges the current view that the development of neovascularizations in AMD represents a harmful event in general Notably before the era of anti-vascular endothelial growths factor VEGF therapy destruction and surgical removal of neovascular membranes have been tested as treatment options for neovascular AMD
This research project aims to substantiate the hypothesis that type 1 macular neovascularization MNV is intrinsically protective in sense of a positive response to the degenerative processes in AMD This concept has actually been proposed by pathologists decades ago but has not been systematically investigated in vivo
With the immense advances in retinal imaging sub-clinical non-exudative type 1 MNVs that are located beneath the retinal pigment epithelium RPE can now be detected non-invasively and characterized in vivo There is currently a growing body of evidence that photoreceptor and RPE degeneration is indeed slowed down in eyes exhibiting type 1 MNV However the proof of a direct protective effect of non-exudative type 1 MNV on visual function in AMD is lacking
Here the aim is to demonstrate relative preservation of function along with preserved structure in the immediate vicinity of type 1 MNV while there is progressive loss of sensitivity and degeneration in the surrounding tissue
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 1R01EY033365-01A1 | NIH | None | httpsreporternihgovquickSearch1R01EY033365-01A1 |